Agios Pharmaceuticals, Inc. $AGIO Position Boosted by Boothbay Fund Management LLC

Boothbay Fund Management LLC increased its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 71.1% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 447,019 shares of the biopharmaceutical company’s stock after purchasing an additional 185,798 shares during the period. Boothbay Fund Management LLC owned 0.77% of Agios Pharmaceuticals worth $14,868,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AGIO. PNC Financial Services Group Inc. lifted its holdings in Agios Pharmaceuticals by 16.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 499 shares during the last quarter. Invesco Ltd. raised its position in shares of Agios Pharmaceuticals by 28.6% during the 1st quarter. Invesco Ltd. now owns 107,367 shares of the biopharmaceutical company’s stock valued at $3,146,000 after acquiring an additional 23,852 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Agios Pharmaceuticals by 207.6% during the 1st quarter. Russell Investments Group Ltd. now owns 8,558 shares of the biopharmaceutical company’s stock valued at $251,000 after acquiring an additional 5,776 shares in the last quarter. E Fund Management Co. Ltd. bought a new position in Agios Pharmaceuticals during the first quarter worth $256,000. Finally, American Century Companies Inc. boosted its holdings in Agios Pharmaceuticals by 9.6% in the first quarter. American Century Companies Inc. now owns 114,947 shares of the biopharmaceutical company’s stock worth $3,368,000 after purchasing an additional 10,110 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on AGIO shares. Truist Financial set a $32.00 target price on shares of Agios Pharmaceuticals in a report on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday. Zacks Research raised shares of Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 4th. Citigroup initiated coverage on Agios Pharmaceuticals in a research note on Wednesday, November 26th. They issued a “buy” rating and a $38.00 target price for the company. Finally, Wall Street Zen cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $35.78.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 3,302 shares of the company’s stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $43.92, for a total value of $145,023.84. Following the completion of the sale, the insider owned 61,727 shares of the company’s stock, valued at $2,711,049.84. This represents a 5.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Cecilia Jones sold 3,651 shares of the stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $36.77, for a total transaction of $134,247.27. Following the completion of the transaction, the chief financial officer owned 33,870 shares of the company’s stock, valued at $1,245,399.90. This represents a 9.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 7,553 shares of company stock valued at $305,001. Company insiders own 4.30% of the company’s stock.

Agios Pharmaceuticals Stock Down 0.7%

Agios Pharmaceuticals stock opened at $27.27 on Friday. The firm has a 50-day moving average price of $36.76 and a two-hundred day moving average price of $36.66. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -3.90 and a beta of 0.87. Agios Pharmaceuticals, Inc. has a 52-week low of $22.24 and a 52-week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.15. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The business had revenue of $12.88 million during the quarter, compared to analyst estimates of $10.49 million. During the same period in the prior year, the company posted $16.22 EPS. The business’s revenue for the quarter was up 43.3% compared to the same quarter last year. Research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.